Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Denali therapeutics inc. save search
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 1.33%
H: 0.25%
C: -1.27%
disease parkinson's health technology biomarkers
Alzheimer's Disease Therapeutics Market size to grow by USD 5.41 billion from 2023-2028; North America to account for 39% of market growth - Technavio
Published: 2023-12-12 (Crawled : 20:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
|
| O: -10.21%
H: 0.0%
C: 0.0%
GIKLY | $4.6 132.75% 4.5K
|
Manufacturing
|
| O: 2.92%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.71%
H: 0.88%
C: 0.85%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.17%
H: 1.17%
C: 0.86%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 2.9%
H: 8.82%
C: 8.56%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.09%
H: 2.58%
C: 2.52%
america disease alzheimer's therapeutics growth market
Parkinson's Disease Therapeutics Market revenue to hit USD 12.32 Billion by 2033, Says We Market Research
Published: 2023-12-06 (Crawled : 15:30) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 1.64%
H: 0.0%
C: -1.33%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.52%
H: 0.18%
C: -0.43%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: -0.03%
H: 0.28%
C: -0.41%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 0.05%
H: 5.74%
C: 3.18%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.42%
H: 2.37%
C: 1.45%
disease parkinson's revenue research therapeutics market
Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight
Published: 2023-04-19 (Crawled : 15:00) - prnewswire.com
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -3.51%
H: 1.28%
C: 0.74%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.17%
H: 0.2%
C: -0.02%
VTGN | $4.69 0.43% 0.43% 200K
|
Health Technology
|
| O: 0.0%
H: 2.59%
C: -0.49%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -1.11%
H: 1.31%
C: 0.56%
BIVI | News | $0.488 3.52% 3.4% 1.4M
|
Health Technology
|
| O: -0.24%
H: 4.29%
C: 0.49%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: -0.39%
H: 0.4%
C: -0.14%
APTX | $0.061 21.31% 7.8M
|
Health Services
|
| O: 2.05%
H: 13.81%
C: 11.81%
AVXL | $3.8 -6.63% -7.11% 1.7M
|
Health Technology
|
| O: -0.74%
H: 2.73%
C: 1.61%
disease companies parkinson's pipeline space trial
Alzheimer's disease therapeutics market size to increase by USD 3.99 billion; North America to account for 37% of market growth - Technavio
Published: 2023-02-08 (Crawled : 01:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.5%
H: 0.17%
C: -2.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.87%
H: 0.17%
C: -1.53%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 2.69%
H: 3.5%
C: 0.13%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 0.79%
H: 0.55%
C: -2.28%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.23%
H: 2.12%
C: 0.31%
america disease alzheimer's therapeutics growth market
Alzheimer's Disease Therapeutics Market Report Research 2022: Increasing Gap of Unmet Need of Effective Therapeutics
Published: 2023-01-20 (Crawled : 00:20) - prnewswire.com
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
| Email alert
Add to watchlist
research disease report alzheimer's therapeutics market
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
Published: 2022-10-03 (Crawled : 12:20) - globenewswire.com
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 2.02%
H: 1.47%
C: -0.86%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 0.75%
H: 0.19%
C: -1.75%
disease parkinson’s therapeutics study
Alzheimer's Disease Therapeutics Market to record USD 3.99 Bn growth -- Driven by the availability, research, and development of novel biomarkers
Published: 2022-09-28 (Crawled : 09:00) - prnewswire.com
GIKLY | $4.6 132.75% 4.5K
|
Manufacturing
|
| O: -6.72%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.94%
H: 2.22%
C: 1.99%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 1.46%
H: 1.25%
C: 0.77%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.76%
H: 0.76%
C: 0.26%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 6.45%
H: 16.46%
C: 10.57%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 43.06%
H: 0.17%
C: -2.24%
disease alzheimer's therapeutics biomarkers growth market
Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease
Published: 2022-05-31 (Crawled : 17:00) - biospace.com/
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 0.08%
H: 1.66%
C: -3.8%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
disease therapeutics phase 2b
Alzheimer's Disease Therapeutics Market 2022-2026 | Availability, Research, and Development of Novel Biomarkers to Boost Growth | Technavio
Published: 2022-04-26 (Crawled : 10:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 1.72%
H: 1.7%
C: -0.29%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.47%
H: 0.83%
C: -1.44%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -0.59%
H: 1.72%
C: -7.7%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: 1.77%
H: 0.71%
C: -2.82%
disease alzheimer's therapeutics growth market alzheimer’s biomarkers
Flagship Pioneering Unveils Vesalius Therapeutics to Revolutionize the Treatment of the Diseases that Drive Ninety Percent of Human Illness
Published: 2022-03-02 (Crawled : 12:00) - biospace.com/
OMGA | $2.42 -5.28% -5.58% 360K
|
|
| O: -6.16%
H: 2.16%
C: -1.62%
SANA | $7.74 -6.3% -6.72% 1.9M
|
|
| O: -5.86%
H: 1.11%
C: -1.8%
SGTX | $22.47 -2.56% 0.0% 0
|
Health Technology
|
| O: -4.0%
H: 5.47%
C: -6.25%
MCRB | $0.589 -6.11% -6.5% 3.8M
|
Health Technology
|
| O: -5.4%
H: 0.0%
C: 0.0%
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: -4.23%
H: 2.21%
C: -0.42%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: -1.93%
H: 0.0%
C: 0.0%
FHTX | $5.58 -3.46% -3.58% 130K
|
Health Technology
|
| O: 2.21%
H: 0.0%
C: -1.67%
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -2.56%
H: 1.97%
C: 0.99%
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -0.59%
H: 2.28%
C: 0.56%
CDAK | $0.057 -55.99% -131.25% 0
|
Health Technology
|
| O: 3.53%
H: 0.0%
C: -3.41%
AXLA | $4.58 -56.33% 42K
|
Health Technology
|
| O: -0.49%
H: 1.49%
C: 1.49%
treatment therapeutics disease one
Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases
Published: 2021-10-26 (Crawled : 18:00) - biospace.com/
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
disease partnership
Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
Published: 2021-07-25 (Crawled : 16:20) - globenewswire.com
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
| Email alert
Add to watchlist
disease phase 1 positive phase 2 syndros mps-ih
Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2030, Foresees DelveInsight
Published: 2021-06-16 (Crawled : 18:00) - prnewswire.com
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
|
| O: 0.16%
H: 1.21%
C: -0.12%
AVXL | $3.8 -6.63% -7.11% 1.7M
|
Health Technology
|
| O: 4.61%
H: 18.52%
C: 16.1%
disease alzheimer growth set alzheimer’s alzheimer's disease alzheimer's
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
Published: 2021-05-01 (Crawled : 16:20) - globenewswire.com
DNLI | $16.6 -1.31% -1.33% 1.2M
|
Health Technology
| Email alert
Add to watchlist
disease positive results phase 1 positive results parkinson phase 3 phase 2 phase 1b phase 2b
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.